Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

79
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
79
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

57
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
57
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

64
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
64

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point-of-Care Ultrasound Curriculum for Internal Medicine Residents During the COVID-19 Era: A Pilot Study.

Cureus·2022
Same author

Drug-Induced Liver Injury After COVID-19 Vaccine.

Cureus·2021
Same author

Scenarios of intermittent E. coli contamination from sewer overflows to shellfish growing waters: The Dart Estuary case study.

Marine pollution bulletin·2021
Same author

Modelling pollution dispersal around Solomon Islands and Vanuatu.

Marine pollution bulletin·2019
Same author

Interleukin-12 and -23 blockade mitigates elastase-induced abdominal aortic aneurysm.

Scientific reports·2019
Same author

Observations on the Dumb-Bell Urinary Deposit.

Edinburgh medical and surgical journal·2018

Related Experiment Video

Updated: May 6, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K

Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report.

Sommer Sekhon1, John Bacon2, Ibaadat Sukhmanii Kahlon3

  • 1Biology, The Smittcamp Family Honors College, California State University (CSU), Fresno, USA.

Cureus
|March 14, 2025
PubMed
Summary

A patient taking semaglutide (Ozempic) developed ischemic colitis, a rare condition. Discontinuing the medication resolved the symptoms, suggesting a potential drug-induced gastrointestinal complication.

Keywords:
drug induced colitisdrug-induced colitisglp1-raischemic colitisozempicsemaglutide

More Related Videos

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.0K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K

Related Experiment Videos

Last Updated: May 6, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K
Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.0K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K

Area of Science:

  • Gastroenterology
  • Clinical Case Reports
  • Pharmacology

Background:

  • Ischemic colitis is typically associated with risk factors like cardiovascular disease.
  • Gastrointestinal side effects are known for GLP-1 receptor agonists like semaglutide.
  • Persistent abdominal pain and bloody diarrhea warrant thorough investigation.

Observation:

  • A 43-year-old female presented with left lower quadrant pain and bloody diarrhea.
  • Initial management for infectious colitis was unsuccessful, with persistent symptoms and imaging findings of pancolitis.
  • Colonoscopy revealed ischemic colitis, prompting discontinuation of semaglutide (Ozempic).

Findings:

  • The patient's symptoms resolved after discontinuing semaglutide.
  • No recurrence of symptoms was noted for several months post-discontinuation.
  • This case suggests a potential link between semaglutide use and ischemic colitis in the absence of typical risk factors.

Implications:

  • Clinicians should consider medication-induced colitis, including ischemic colitis, in patients with unexplained gastrointestinal symptoms.
  • Evaluating medication history is crucial, especially when typical risk factors for ischemic colitis are absent.
  • Further research may be needed to establish a definitive causal relationship between semaglutide and ischemic colitis.